By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile



1334 Main Road

Tiverton  Rhode Island  02878  U.S.A.
Phone: 401-816-0525 Fax: 401-816-0524



Start Up

Company News
VeroScience Is Pleased To Support Independent Research From The Laboratory Of Dr. Defronzo And Team At UT Health Science Center, San Antonio 6/13/2016 11:04:09 AM
VeroScience Continues To Explore Clinical Benefits Of Circadian Neuroendocrine Resetting Therapy With Six Papers Presented At 2016 American Diabetes Association Scientific Sessions June 10-14 6/13/2016 11:01:06 AM
Published Review Paper From VeroScience Delineates 50 Years Of Research Linking Circadian Rhythms With Metabolic Disease 3/16/2016 10:27:23 AM
VeroScience Release: Two Peer-Reviewed Studies Focusing On Unique Therapeutic Impact Of Veroscience's Cycloset Recently Published In Journal Of Diabetes Research 6/15/2015 7:59:49 AM
VeroScience Continues Clinical Evaluation of Bromocriptine-QR (Cycloset) And Neurophysiological Investigations Of Brain Dopamine Regulation Of Metabolism With Eight Papers Presented At The 2015 American Diabetes Association Conference 6/8/2015 6:46:34 AM
Santarus Inc. (SNTS) and VeroScience Announce CYCLOSET (bromocriptine mesylate) Data Presentations at the American Diabetes Association Meeting 6/21/2013 7:00:01 AM
Santarus Inc. (SNTS) and VeroScience Announce Publication of American Association of Clinical Endocrinologists Expert Panel Recommendations for CYCLOSET® (bromocriptine mesylate) for the Management of Type 2 Diabetes 3/6/2013 9:57:25 AM
Santarus Inc. (SNTS) and VeroScience Announce Publication of Positive Data From Pivotal CYCLOSET® (bromocriptine mesylate) Efficacy Study 1/23/2013 9:41:13 AM
Santarus Inc. (SNTS) Buys License To Make Diabetes Drug For $5 Mln From S2 Biosciences Inc. And VeroScience 9/9/2010 6:53:42 AM
VeroScience Announces FDA Approval of Cycloset for Treatment of Type 2 Diabetes 5/6/2009 8:33:07 AM